Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 667-675

  Goy, Andre ^a   Younes, Anas ^a   McLaughlin, Peter ^a   Pro, Barbara ^a   Romaguera, Jorge E ^a   Hagemeister, Frederick ^a   Fayad, Luis ^a   Dang, Nam H ^a   Samaniego, Felipe ^a   Wang, Michael ^a   Broglio, Kristine ^a   Samuels, Barry ^a   Gilles, Frederic ^a   Sarris, Andreas H ^a   Hart, Susan ^a   Trehu, Elizabeth ^a   Schenkein, David ^a   Cabanillas, Fernando ^a   Rodriguez, Alma M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER FATIGUE; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; LYMPHOCYTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NECROTIZING ARTERITIS; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20044396543     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.108     Document Type: Article

References (30)

1. Chiu BC, Weisenburger DD: An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 4:161-168, 2003
2. Coiffier B, Thieblemont C, Felman P, et al: Indolent nonfollicular lymphomas: Characteristics, treatment, and outcome. Semin Hematol 36:198-208, 1999
3. Barista I, Romaguera JE, Cabanillas F: Mantle-cell lymphoma. Lancet Oncol 2:141-148, 2001
4. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
5. Romaguera JE, Khouri IF, Kantarjian HM, et al: Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39:77-85, 2000
6. Zeeb H, Blettner M: Increasing incidence and mortality of non-Hodgkin lymphomas: An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma. Med Klin (Munich) 96:87-100, 2001
7. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999
8. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 426:895-899, 2003
9. Mack PC, Davies AM, Lara PN, et al: Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41:S89-S96, 2003 (suppl 1)
10. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002
11. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534, 2003
12. Kane RC, Bross PF, Farrell AT, et al: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508-513, 2003
13. Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappaB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88-95, 2003
14. Bogner C, Ringshausen I, Schneller F, et al: Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol 122:260-268, 2003
15. Pham L, Tamayo A, Lo P, et al: Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 98:1945, 2001 (abstr 1945: suppl)
16. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologie malignancies. J Clin Oncol 20: 4420-4427, 2002
17. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
18. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172, 2004
19. Aghajanian C, Soignet S, Dizon DS, et al: A phase 1 trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
20. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
21. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
22. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 22:566, 2003 (abstr 2277)
23. Assouline S, Belch A, Sehn L, et al: A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 107:902a, 2003 (abstr 3358)
24. O'Connor OA: Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 22:5785, 2004 (abstr 6582)
25. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003
26. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540, 2001
27. Orlowski R, Hall M, Voorhees P, et al: Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (Doxil) in patients with refractory hematologic malignancies. Blood 100:105a, 2002 (abstr 388)
28. Dunleavy KM, Janik J, Grant N, et al: Phase I/II study of bortezomib combined with dose adjusted-EPOCH chemotherapy in relapsed or refractory diffuse large B-cell lymphomas. Blood 102: 636a, 2003 (abstr 2349)
29. Richardson P: Clinical update: Proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29:33-39, 2003 (suppl 1)
30. Lonial S, Waller EK, Richardson PG, et al: Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 102:447a, 2003 (abstr 1632)